


WE CLAIM:

1. A compound of formula I:



(I)

5 wherein:

- Ar¹ is a cyclic group optionally substituted with one to five groups selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, hydroxy, C₁-C₈ alkoxy, C₁-C₈ alkylaryl, phenyl, aryl, -O-aryl, heteroaryl, cycloalkyl, C₁-C₈ alkylcycloalkyl, cyano, -(CH₂)_nNR⁶R⁶, C₁-C₈ haloalkyl, C₁-C₈ haloalkoxy, halo, (CH₂)_nCOR⁶, (CH₂)_nNR⁵SO₂R⁶, -(CH₂)_nC(O)NR⁶R⁶,
 10 heterocyclic, and C₁-C₈ alkylheterocyclic; wherein the cycloalkyl, phenyl, aryl, and heterocyclic groups are each optionally substituted with one to three groups independently selected from hydroxy, C₁-C₈ alkoxyalkyl, C₁-C₈ haloalkoxy, C₁-C₈ alkyl, halo, C₁-C₈ haloalkyl, nitro, cyano, amino, carboxamido, phenyl, aryl, alkylheterocyclic, heterocyclic, and oxo;
- 15 L¹ is a bond or a divalent linker represented by the formula X₂-(CR³R⁴)_m-X₃ where X₂ is attached to Ar¹ and X₃ is attached to Ar² wherein R³ and R⁴ are independently selected from a bond, hydrogen, C₁-C₈ alkyl, C₂-C₈ alkylene, C₂-C₈ alkynyl, phenyl, aryl, C₁-C₈ alkylaryl; wherein the alkyl, alkenyl, phenyl, and aryl groups are optionally substituted with one to five substituents independently selected from oxo, nitro, cyano, C₁-C₈ alkyl,
 20 aryl, halo, hydroxy, C₁-C₈ alkoxy, C₁-C₈ haloalkyl, (CH₂)_nC(O)R⁶, and (CH₂)_nCONR⁶R⁶;
- X₂ is independently oxygen, -CH, -CONH(CR³R⁴)_m, -NHCO(CR³R⁴)_m, -(CR³R⁴)_m, -CHR⁶, -NR⁵, S, SO, SO₂, -O(CR³R⁴)_m, or -S(CR³R⁴)_m;
- X₃ is independently oxygen, -C, -CH, -CHR⁶, -(CR³R⁴)_m, -NR⁵, S, SO, or SO₂;
- 25 Ar² is a 5-member monocyclic heterocyclic aromatic group or positional isomer thereof, having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and wherein Ar² is optionally substituted with one to three substituents independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, hydroxy, C₁-C₈ alkoxy, C₁-C₈ alkylaryl, phenyl, aryl, C₃-C₈ cycloalkyl, C₁-C₈ alkylcycloalkyl, cyano, C₁-C₈ haloalkyl,

halo, $(\text{CH}_2)_n\text{C}(\text{O})\text{R}^6$, $(\text{CH}_2)_n\text{C}(\text{O})\text{OR}^6$, $(\text{CH}_2)_n\text{NR}^5\text{SO}_2\text{R}^6$, $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$, and $\text{C}_1\text{-C}_8$ alkylheterocyclic;

Ar^3 is an optionally substituted bicyclic aromatic or non-aromatic group;

L^2 is a divalent linker represented by the formula $\text{X}_4\text{-(CR}^3\text{R}^4)_m\text{-X}_5$;

5 wherein X_4 is selected from the group consisting of C, $-\text{CH}$, CHR^6 , $-\text{CO}$, O, $-\text{NR}^5$, $-\text{NC}(\text{O})-$, $-\text{NC}(\text{S})$, $-\text{C}(\text{O})\text{NR}^5-$, $-\text{NR}^{6'}\text{C}(\text{O})\text{NR}^6$, $-\text{NR}^{6'}\text{C}(\text{S})\text{NR}^6$, $-\text{SO}_2\text{NR}^7$, $-\text{NRSO}_2\text{R}^7$, and $-\text{NR}^{6'}\text{C}(\text{NR}^5)\text{NR}^6$;

X_5 is selected from the group consisting of O, $-\text{CH}_2$, $-\text{CH}$, $-\text{O}(\text{CR}^3\text{R}^4)_m$, $\text{NR}^3(\text{CR}^3\text{R}^4)_m$, SO, SO_2 , S, and SCH_2 ; wherein the group $\text{X}_4\text{-(CR}^3\text{R}^4)_m\text{-X}_5$ imparts stability to the

10 compound of formula (1) and may be a saturated or unsaturated chain or divalent linker;

R^1 and R^2 are independently hydrogen, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_1\text{-C}_8$ alkylaryl, $-\text{C}(\text{O})\text{C}_1\text{-C}_8$ alkyl, $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ alkylcycloalkyl,

$(\text{CH}_2)_n\text{C}(\text{O})\text{OR}^5$, $(\text{CH}_2)_n\text{C}(\text{O})\text{R}^5$, $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$, and $(\text{CH}_2)_n\text{NSO}_2\text{R}^5$; wherein each of the alkyl, alkenyl, aryl are each optionally substituted with one to five groups

15 independently selected from $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, phenyl, and alkylaryl; and

wherein R^1 and R^2 may combine together, and with the nitrogen atom to which they are attached or with 0, 1, 2 or 3 atoms adjacent to the nitrogen atom to form a nitrogen containing heterocycle which may have 1, or 2 substituents independently selected from

20 $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_1\text{-C}_8$ alkylaryl, $-\text{C}(\text{O})\text{C}_1\text{-C}_8$ alkyl, $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ alkylcycloalkyl, oxo, halo amino, and $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$;

R^5 is hydrogen, CN, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_5\text{-C}_8$ alkylaryl, $(\text{CH}_2)_n\text{NSO}_2\text{C}_1\text{-C}_8$ alkyl, $(\text{CH}_2)_n\text{NSO}_2$ phenyl, $(\text{CH}_2)_n\text{NSO}_2$ aryl, $-\text{C}(\text{O})\text{C}_1\text{-C}_8$ alkyl, or $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$ alkyl; and

R^6 and $\text{R}^{6'}$ are each independently hydrogen, $\text{C}_1\text{-C}_8$ alkyl, phenyl, aryl, $\text{C}_1\text{-C}_8$ alkylaryl, $\text{C}_1\text{-C}_8$ alkylcycloalkyl, or $\text{C}_3\text{-C}_8$ cycloalkyl;

25 R^7 is hydrogen, $\text{C}_1\text{-C}_8$ alkyl, phenyl, aryl, $\text{C}_1\text{-C}_8$ alkylaryl, or $\text{C}_3\text{-C}_8$ cycloalkyl, and wherein m is an integer from 1 to 8; and n is an integer from 0 to 8;

or a pharmaceutically acceptable salt, solvate, racemate, or enantiomer diastereomer or mixture of diastereomers thereof.

30 2. A compound according to Claim 1 wherein the group Ar^1 is selected from the group consisting of: phenyl, benzothiophene, benzofuran, or naphthyl.

3. A compound according to Claim 1 wherein the group L^1 is a linker selected from the group consisting of: $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-SCH_2-$, $-OCH_2-$, $-CH_2SCH_2-$, $-CH_2OCH_2-$, or $-OCH_2CH_2SCH_2-$.
- 5 4. A compound according to Claim 1 wherein Ar^3 is an aromatic group selected from the group consisting of: indole, naphthyl, tetrahydronaphthyl, isoindolinone, isoquinolone, benzothiophene, or benzofuran.
- 10 5. A compound of Claim 1 wherein Ar^2 is a 4 or 5 member aromatic group selected from the group consisting of: oxazole, oxadiazole, or furan.
6. A compound according to Claim 1 wherein the linker (L^2) is: $-CH_2-$, $-CH_2CH_2-$, or $-CH_2CH_2CH_2-$.
- 15 7. A compound according to Claim 1 wherein R^1 and R^2 combine with the nitrogen atom to form piperidinyl, pyrrolidinyl, azepine, or azetidiny.
8. A compound according to Claim 1 wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, 20 methylcyclopentane, methylcyclohexane, phenyl, benzyl, cyclopentyl, cyclohexyl, methylcyclopropane and methylcyclobutane.
9. A compound according to Claim 1 wherein the group Ar^3 is naphthyl group.
- 25 10. A compound according to Claim 7 wherein the group Ar^2 is selected from oxazole or oxadiazole.
11. A compound according to Claim 8 wherein the group Ar^2 is selected from oxazole or oxadiazole.
- 30 12. A compound according to Claim 1 wherein at least one of L^1 and L^2 has a chain length of 3 to 5 atoms.

13. A compound selected from the group consisting of:

Dimethyl-{ 6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-benzofuran-2-ylmethyl}-amine oxalate,

5 Dimethyl-{ 5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-benzofuran-2-ylmethyl}-amine oxalate,

{ 1-Methanesulfonyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,

10 Dimethyl-{ 5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,

{ 1-Methanesulfonyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,

Dimethyl-{ 6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine,

15 Dimethyl-{ 1-methyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,

Dimethyl-{ 5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,

20 Dimethyl-{ 6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine maleate,

Dimethyl-{ 1-methyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,

Dimethyl-{ 4-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-1-yl}-amine,


25 Dimethyl-{ 6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-amine,

2-(2-Phenoxy-ethylsulfanylmethyl)-5-(6-pyrrolidin-1-ylmethyl-naphthalen-2-yl)-[1,3,4]oxadiazole maleate,

30 1-{ 6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-piperidine,

- 2-(2-piperidinoethyl)-5-{2-[(2-phenoxyethyl)thio)methyl]-1,3,4-oxadiazol-5-yl}isoindolin-1-one,
 2-[(2-Phenoxyethyl)thio)methyl]-5-{3-hydroxymethyl-4-[(2-piperidinoethyl)amino)carbonyl]phenyl}-1,3,4-oxadiazolo,
 5 2-(2-piperidinoethyl)-5-{2-[(2-phenoxyethyl)thio)methyl]-1,3,4-oxadiazol-5-yl}isoindolin-1-one, and pharmaceutically acceptable salt, solvate, enantiomer, prodrug, diastereomer or mixture thereof.

14. A compound selected from the group consisting of:



or pharmaceutically acceptable salt, racemate, solvate, enantiomer or diastereomer or mixture of diastereomers thereof.

15

15. The compound of any one of Claims 1-14 which is the hydrochloride salt.

16. A method of treating Type II Diabetes comprising administering to a patient in need thereof a compound of any one of Claims 1-14.

20

17. A method of treating obesity and Related Diseases comprising administering to a patient in need thereof a compound of any one of Claims 1-14.

18. A method of inhibiting release of the melanin concentrating hormone comprising administering to a patient in need thereof a compound of any one of Claims 1-14.

5 19. A pharmaceutical formulation comprising a compound of any one of Claims 1-14 and a pharmaceutical carrier.

20. Use of a compound according to any one of Claims 1-14 for the manufacture of a medicament for treating and/or preventing Type II diabetes, obesity
10 and/or Related Diseases.